Core Viewpoint - Abivax SA has resumed trading of its ordinary shares on Euronext Paris following a halt related to a public offering of American Depositary Shares [1][2]. Group 1: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [3]. - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis [3]. Group 2: Trading Information - Trading of Abivax's ordinary shares was halted on July 24, 2025, at 9:00 a.m. CEST at the company's request to facilitate a public offering in the United States [2]. - The trading resumed at 3:30 p.m. CEST on the same day [1].